Video

Dr. Davies on the Utility of Retreatment With BRAF/MEK Inhibitors in BRAF-Mutant Melanoma

Michael A. Davies, MD, PhD, discusses the utility of retreatment with combination BRAF/MEK inhibitors in BRAF-mutant melanoma.

Michael A. Davies, MD, PhD, Anne and John Mendelsohn Chair in Cancer Research, professor and chair, Department of Melanoma Medical Oncology, Division of Cancer Medicine, co-leader, Melanoma Moon Shot Program, Department of Moon Shots Program, director of research activities, Department of Hematology/Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center, discusses the utility of retreatment with combination BRAF/MEK inhibitors in BRAF-mutant melanoma.

Typically, patients who progress on a BRAF/MEK inhibitor combination will not respond to another BRAF/MEK inhibitor regimen if it is given consecutively, says Davies. However, patients who require a significant dose reduction on 1 regimen may derive efficacy from another if they are able to tolerate the second combination at a higher dose, Davies explains.

Additionally, resistance to BRAF/MEK inhibitors is not necessarily permanent in patients with BRAF-mutant melanoma, Davies adds. Patients who progress on a BRAF/MEK combination and subsequently receive another treatment, such as immunotherapy for 3 months, may be rechallenged with another BRAF/MEK combination upon progression on immunotherapy, explains Davies. Data have reported good disease control rates with this approach, Davies concludes.

Related Videos
Dr Patel on the Utility of the IPS Test in Solid Tumors
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Alison Schram, MD
Shaji Kumar, MD
Kevin Kalinsky, MD, MS
Guru P. Sonpavde, MD
Matthew P. Deek, MD
Peter Schmid, MD, PhD, FRCP, discusses updated KEYNOTE-522 data showing that pembrolizumab plus chemotherapy improves EFS in early-stage TNBC.
Guru P. Sonpavde, MD
David Rimm, MD, PhD